1. Sanfeng Dong,# Hui Huang,# Jintian Li,# Xiaomei Li, Samuel Jacob Bunu, Yun Yang, Yong Zhang, Qi Jia, Zhijian Xu, Yingxia Li*, Hu Zhou*, Bo Li,* Weiliang Zhu*, Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads. Commun Chem. 2024 Sep 9; 7(1): 201. (IF 5.9/2023)

2. Hui Zhang,# Ke Hu,# Yumeng Lu, Zhijian Xu, Gege Chen, Dandan Yu, Xuejie Gao, Qilin Feng, Xinyan Jia, Li Xu, Jinfeng Zhou, Xiaosong Wu, Dongliang Song, Huabin Zhu, Bo Li,* Weiliang Zhu*, Jumei Shi*，A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory，Int Immunopharmacol. 2024 Jan 25; 127(5):111446. (IF 5.6/2023)

3. Sanfeng Dong,# Ke Hu,# Yulong Shi,# Guanli Wang,# Dandan Yu, Yitian Zhao, Hui Zhang, Yingcong Wang, Haiguo Sun, Zhijian Xu, Qi Jia, Yiming Li, Yingxia Li, Bo Li,* Jumei Shi*, Weiliang Zhu*, Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo. Bioorg Med Chem Lett. 2024 Jan 15; 98:129590.

4. Qilin Feng,# Ke Hu,# Huifang Hu, Yumeng Lu, Hui Zhang, Guanli Wang, Qikai Zhang, Zhijian Xu, Xuejie Gao, Xinyan Jia, Huabin Zhu, Dongliang Song, Hongfei Yi, Yu Peng, Xiaosong Wu, Bo Li,* Weiliang Zhu,* Jumei Shi.* Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells. Int Immunopharmacol. 2023, 125, 111139. (IF 5.6/2023)

5. Hongkai Yuan,# Bo Li,# Leyun Wu,# Xue-Ling Wang, Zhi-Ying Lv, Zhikai Liu, Zhijian Xu, Jin Lu, Cai-Tao Chen, Yongqing Yang,* Weiliang Zhu,* Leimiao Yin,* Discovery of zolinium TSG1180 as a novel agonist of transgelin-2 for treating asthma, Biomed Pharmacother. 2023 Sep 29; 167: 115556. (IF 7.419/2022)

6. Shiwei Lu,# Feng Zhang,# Jiahao Gong,# Jian Huang, Guanghao Zhu, Yitian Zhao, Qi Jia, Yiming Li, Bo Li,* Kaixian Chen, Weiliang Zhu,* Guangbo Ge,* Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors，Bioorg Med Chem Lett. 2023 Aug 6; 95: 129435.

7. Yitian Zhao1, Min Zhang1, Xudong Hou1, Jiaxin Han, Xiaoya Qin, Yun Yang, Yunqing Song, Zhikai Liu, Yong Zhang, Zhijian Xu, Qi Jia, Yiming Li, Kaixian Chen, Bo Li,* Weiliang Zhu*, Guangbo Ge*, Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase，Bioorg Med Chem. 2023 Aug 15; 91: 117413.

8. Yun Yang,# Yuan Xiong,# Guanghao Zhu,# Mengru Sun, Kun Zou, Yitian Zhao, Yong Zhang, Zhijian Xu, Yiming Li, Weiliang Zhu, Qi Jia,* Bo Li,* Guangbo Ge,* Discovery of seven-membered ring berberine analogues as highly potent and specific hCES2A inhibitors, Chem Biol Interact. 2023 Apr 18, 378, 110501. (IF 5.168/2022)

9. Bibo Zhang,# Bo Li,# Yongsheng Xie, Shuaikang Chang, Zhijian Xu, Huifang Hu, Gege Chen, Ting Zhang, Jun He, Xiaosong Wu, Huabin Zhu, Weiming Lai, Dongliang Song, Ying Lu, Xinyan Jia,* Weiliang Zhu,* Jumei Shi,* A novel alkaloid compound, DCZ0358 exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway. Acta Biochimica et Biophysica Sinica. 2023 Feb 22, 55(2) 1–10（IF 3.511/2022）

10. Huiying Zhang,# Bo Li,# Jingjuan Ding,# RongYe, Zhijian Xu, Qiuyang Zhang, Siguo Feng, Qin Jiang,* Weiliang Zhu,* BiaoYan,* DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization. Sci Rep. 2022 Dec 13; 12(1):21539. (IF 4.996/2022)

11. Jingjuan Ding,# Bo Li,# Huiying Zhang,# Zhijian Xu, Qiuyang Zhang, Rong Ye, Siguo Feng, Qin Jiang,* Weiliang Zhu,* and Biao Yan,* Suppression of pathological ocular neovascularization by a small molecular multi-targeting kinase inhibitor, DCZ19903. Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903. Transl Vis Sci Technol. 2022 Dec 1; 11(12): 8. (IF 3.048/2022)

12. Haiguo Sun,# Mengyu Xi,# Qiang Jin,# Zhengdan Zhu, Yani Zhang, Guihua Jia, Guanghao Zhu, Mengru Sun, Hongwei Zhang, Xuelian Ren, Yong Zhang, Zhijian Xu, He Huang, Jingshan Shen, Bo Li,* Guangbo Ge,* Kaixian Chen, Weiliang Zhu.* Chemo- and Site-Selective Lysine Modification of Peptides and Proteins under Native Conditions Using the Water-Soluble Zolinium. J Med Chem. 2022 Aug; 65, 17, 11840–11853. (IF 8.039/2022)

13. Shuaikang Chang,# Bo Li,# Yongsheng Xie,# Yingcong Wang, Zhijian Xu, Shuhan Jin, Dandan Yu, Huaping Wang, Yumeng Lu, Yong Zhang, Ruye Ma, Cheng Huang, Weiming Lai, Xiaosong Wu, Weiliang Zhub,* Jumei Shi,* DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway, Neoplasia, 2022 Jan;24(1):50-61. (IF 6.218/2022)

14. Wenxuan Bu,# Bo Li,# Lijin Feng,# Qilin Feng, Ke Hu, Zhijian Xu, Yingcong Wang, Mengyu Xi, Houcai Wang, Guang Yang, Xiaosong Wu, Weiliang Zhu,* Jumei Shi,* A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling. Am J Transl Res. 2021 Oct 15;13(10):11439-11449. (IF 4.060/2021)

15. Bo Li,# Heng Li,# Zhengdan Zhu,# Caigui Xiang, Zhijian Xu, Chen Fan, Yitian Zhao, Chunlan Feng, Haiguo Sun, Yong Zhang, Tingting Cai, Wei Tang,* Weiliang Zhu.* Discovery of Chiral N-2’-aryletheryl-1’-alkoxy-ethyl substituted arylisoquinolones with anti-inflammatory activity from the nucleophilic addition reactions of the thiophenols and oxazolinium, Eur J Med Chem. 2021 Jun 1;222:113583. (IF 6.514/2021)

16. Xuejie Gao,# Bo Li,# Houcai Wang,# Yongsheng Xie, Dandan Yu, Zhijian Xu, Bingqing Shi, Hui Zhang, Qilin Feng, Ke Hu, Yong Zhang, Cheng Huang, Guang Yang, Jumei Shi,* Weiliang Zhu.* A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway. Cancer Cell Int. 2021 May 30; 21(1): 285. (IF 5.722/2021)

17. Ke Hu,# Bo Li,# Ruye Ma,# Hongfei Yi, Zhijian Xu, Yu Peng, Dandan Yu, Huiqun Wu, Taofang Cheng, Yumeng Lu, Yong Zhang, Rong Wei, Guang Yang, Xiaosong Wu, Weiliang Zhu,* Jumei Shi.* Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K−AKT−mTOR/JNK pathway. Acta Biochim Biophys Sin (Shanghai). 2021 Apr 15; 53(5):575-583. (IF 3.848/2021)

18. Sanfeng Dong, # Yitian Zhao, # Yulong Shi, # Zhijian Xu, Jingshan Shen, Qi Jia,* Yiming Li, Kaixian Chen, Bo Li,* Weiliang Zhu.* One step stereoselective synthesis of oxazolinefused saccharides and their conversion into the corresponding 1,2-cis glycosylamines bearing various protected groups, Org Biomol Chem. 2021 Feb 25;19(7):1580-1588. (IF 3.876/2021)

19. Kai Xu, # Bo Li, # Shujie Zhang, # Fangyuan Hu, Zhijian Xu, Lei Li, Yihan Zhang, Weiliang Zhu,* Chen Zhao,* DCZ3301, An Aryl-guanidino Agent, Inhibits Ocular Neovascularization via PI3K/AKT and ERK1/2 Signaling Pathways, Exp Eye Res. 2020 Sep 25;108267. (IF 3.467/2020)

20. Yitian Zhao, # Yuan Xiong, # Sanfeng Dong, # Xiaoqing Guan, # Yunqing Song, Kun Zou, Zhao Li, Yong Zhang, Shengquan Fang, Bo Li,* Weiliang Zhu, Kaixian Chen, Qi Jia,* Guangbo Ge,* Discovery of 3-arylisoquinolone analogues as novel highly selective hCES2A inhibitors, ChemMedChem. 2020 Sep 16, 15, 1–12. (IF 3.466/2020)

21. Qilin Feng, # Qingchun Yao, # Bo Li, # Yongsheng Xie, Yao Cheng, Zhijian Xu, Ke Hu, Bingqing Shi, Cheng Huang, Liping Li, Xiaosong Wu, Shanxi You,* Jumei Shi,* Weiliang Zhu,* Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in multiple myeloma. J Cancer. 2020 Jun 15; 11(16):4907-4916. (IF 4.207/2020)

22. Liangning Hu, # Bo Li, # Gege Chen, # Dongliang Song, Zhijian Xu, Lu Gao, Mengyu Xi, Jinfeng Zhou, Liping Li, Hui Zhang, Qilin Feng, Yingcong Wang, Kang Lu, Yumeng Lu, Wenxuan Bu, Houcai Wang, Xiaosong Wu, Weiliang Zhu,* Jumei Shi,* A novel M phase blocker, DCZ3301 overcomes bortezomib resistance in multiple myeloma by inducing DNA damage and mitotic catastrophe. J Exp Clin Cancer Res. 2020 Jun 9; 39(1): 105. (IF 11.161/2020)

23. Kang Lu, # Bo Li, # Hui Zhang, # Zhijian Xu, Dongliang Song, Lu Gao, Haiguo Sun, Liping Li, Yingcong Wang, Qilin Feng, Gege Chen, Liangning Hu, Rong Wei, Yongsheng Xie, Dandan Yu, Xiaosong Wu, Weiliang Zhu,* Jumei Shi.* A Novel Silicone Derivative of Natural Osalmid (DCZ0858) Induces Apoptosis and Cell Cycle Arrest in Diffuse Large B-cell Lymphoma via the JAK2/STAT3 Pathway. Signal Transduct Target Ther. 2020 Apr 1; 5(1): 31. (IF 18.187/2020)

24. Mengyu Xi, # Wan He, # Bo Li,* Jinfeng Zhou, Zhijian Xu, Huiqun Wu, Yong Zhang, Dongliang Song, Liangning Hu, Ye Lu, Wenxuan Bu, Yuanyuan Kong, Gege Chen, Shuaikang Chang, Jumei Shi,* Weiliang Zhu,* Novel cyclophosphamide of natural products osalmide and pterostilbene induces cytotoxicity and cell cycle arrest in diffuse large B-cell lymphoma cells, Acta Biochim Biophys Sin (Shanghai). 2020 Apr 20; 52(4): 401-410. (IF 3.848/2020)

25. Gege Chen, # Ke Hu, # Haiguo Sun, Jinfeng Zhou, Dongliang Song, Zhijian Xu, Lu Gao, Ye Lu, Yao Cheng, Qilin Feng, Hui Zhang, Yingcong Wang, Liangning Hu, Kang Lu, Xiaosong Wu, Bo Li,* Weiliang Zhu,* Jumei Shi.* A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Cancer Lett. 2020 Mar 8, 478: 45-55. (IF 8.679/2020)

26. Yingcong Wang,# Jing Huang,# Bo Li,# Han Xue, Guido Tricot, Liangning Hu, Zhijian Xu, Xiaoxiang Sun, Shuaikang Chang, Lu Gao, Yi Tao, Hongwei Xu, Yongsheng Xie, Wenqin Xiao, Dandan Yu, Yuanyuan Kong, Gege Chen, Xi Sun, Fulin Lian, Naixia Zhang, Xiaosong Wu, Zhiyong Mao, Fenghuang Zhan, Weiliang Zhu*, and Jumei Shi*. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2020 Feb 1;80(3):536-548.（IF 12.701/2020）

27. Peng Liu, Bo Li,* Mengyu Xi, Zhaoqiang Chen, Haiguo Sun, Xiajuan Huan, Xuejun Xu, Yong Zhang, Kun Zou, Xiangrui Jiang, Zehong Miao, Jinggen Liu, Jingshan Shen, Kaixian Chen, Weiliang Zhu*. Metal-free quinolylation of the primary amino groups of amino acid derivatives and peptides with dihydrooxazolo[3,2-a]quinoliniums. Green Chem., 2019 July 12, 21, 4231 – 4237.（IF 9.480/2019）

28. Lixia Ding,# Lu Wang,# Kun Zou,# Bo Li,* Yunqing Song, Qihua Zhang, Yitian Zhao, Zhijian Xu, Guangbo Ge,* Bo Zhao* and Weiliang Zhu*. Discovery of dihydrooxazolo[2,3-a]isoquinoliniums as highly specific inhibitors of hCE2. RSC Adv., 2019, 9, 35904-35912 (IF 3.119/2019)

29. Ting Zhang,# Bo Li,# Qilin Feng,# Zhijian Xu, Cheng Huang, Huiqun Wu, Zhangbo Chen, Liangning Hu, Lu Gao, Peng Liu, Guang Yang, Hui Zhang, Kang Lu, Tingye Li, Yi Tao, Xiaosong Wu, Jumei Shi*, and Weiliang Zhu*. DCZ0801, a novel compound, induces cell apoptosis and cell cycle arrest via MAPK pathway in multiple myeloma. Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):517-523.  (IF 2.502/2018)

30. Yuanyuan Kong,# Bo Li,# Shuaikang Chang, Lu Gao, Zhijian Xu, Wan He, Guang Yang, Bingqian Xie, Gege Chen, Liangning Hu, Kang Lu, Yingcong Wang, Xiaosong Wu, Weiliang Zhu*, and Jumei Shi*. DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2. Cancer Manag Res, 2019 May 27;11:4797-4808. (IF 2.243 / 2018)

31. Peng Liu,# Xiangling Chen,# Jianming Zhu, Bo Li,* Zhaoqiang Chen, Guimin Wang, Haiguo Sun, Zhijian Xu, Zhixin Zhao, Chen Zhou, Chengying Xie*, Liguang Lou*, Weiliang Zhu*, Design, synthesis and pharmacological evaluation of novel Hsp90 N-terminal inhibitors without induction of heat shock response. ChemistryOpen, 2019 Mar 28;8(3):344-353.（IF 2.205/2018）

32. Yongsheng Xie,# Bo Li,# Wenxuan Bu, Lu Gao, Yong Zhang, Xiucai Lan, Jun Hou, Zhijian Xu, Shuaikang Chang, Dandan Yu, Bingqian Xie, Yingcong Wang, Houcai Wang, Yiwen Zhang, Xiaosong Wu, Weiliang Zhu*, Jumei Shi*. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2. Int J Oncol. 2018, 53(2): 823-834.  (IF 3.333 / 2017)

33. Lu Gao,# Bo Li,# Guang Yang,# Peng Liu, Xiucai Lan, Shuaikang Chang, Yi Tao, Zhijian Xu, Bingqian Xie, Xi Sun, Yingcong Wang, Liangning Hu, Dandan Yu, Yongsheng Xie, Wenxuan Bu, Xiaosong Wu, Weiliang Zhu*, Jumei Shi*. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment. Cancer Lett. 2018 May 1;421:135-144.  (IF 6.491 / 2017)

34. Minjie Gao,# Bo Li,# Xi Sun,# Yunfei Zhou, Yingcong Wang, Van S. Tompkins, Zhijian Xu, Nekitsing Indima, Houcai Wang, Wenqin Xiao, Lu Gao, Gege Chen, Huiqun Wu, Xiaosong Wu, Yuanyuan Kong, Bingqian Xie, Yiwen Zhang, Gaomei Chang, Liangning Hu, Guang Yang, Bojie Dai, Yi Tao*, Weiliang Zhu* and Jumei Shi*, Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma, Theranostics, 2017 Aug 23;7(15):3690-3699.  (IF 8.712 / 2016)

35. Xi Sun,# Bo Li,# Bingqian Xie,# Zhijian Xu, Gaomei Chang, Yi Tao, Yong Zhang, Shuaikang Chang, Yingcong Wang, Dandan Yu, Yongsheng Xie, Tingye Li, Houcai Wang, Gege Chen, Liangning Hu, Jun Hou, Yiwen Zhang, Wenqin Xiao, Lu Gao, Weiliang Zhu* and Jumei Shi*, DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B cell lymphoma via the STAT3 pathway, Cell Death Dis., 2017 Oct 12;8(10):e3111.  (IF 5.965 / 2016)

36. Liangning Hu,# Huiqun Wu,# Bo Li,# Dongliang Song, Guang Yang, Gege Chen, Bingqian Xie, Zhijian Xu, Yong Zhang, Dandan Yu, Jun Hou, Wenqin Xiao, Xi Sun, Gaomei Chang, Yiwen Zhang, Lu Gao, Bojie Dai, Yi Tao,* Jumei Shi,* and Weiliang Zhu,* Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo, Acta Biochim Biophys Sin (Shanghai). 2017, 49(5): 420-427.（IF 2.200 / 2016）

37. Bo Li,# Susu Xue,# Yang Yang,# Jia Feng,# Peng Liu, Yong Zhang, Jianming Zhu, Zhijian Xu, Adrian Hall, Bo Zhao,* Jiye Shi,* and Weiliang Zhu,* Regioselectivity and Mechanism of Synthesizing N-Substituted 2-Pyridones and 2-Substituted Pyridines via Metal-Free C-O and C-N Bond-Cleaving of Oxazoline[3,2-a]pyridiniums, Sci Rep. 2017 Jan 25;7:41287.（IF 4.259 / 2016）

38. Guoxin Du,# Yuanyuan Zhao,# Li Feng, Zhuo Yang, Jiye Shi, Cheng Huang, Bo Li,* Fujiang Guo*, Weiliang Zhu, Yiming Li. Design, Synthesis, and Structure–Activity Relationships of Bavachinin Analogues as Peroxisome Proliferator-Activated Receptor γ Agonists, ChemMedChem. 2017 Jan 20;12(2):183-193.（IF 3.225 / 2016）

39. Kun Zou, Zhao Li, Yong Zhang, Hao-yue Zhang, Bo Li,* Wei-liang Zhu, Ji-ye Shi*, Qi Jia*, Yi-ming Li. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system, Acta Pharmacol Sin. 2017 Feb;38(2):157-167. （IF 3.223 / 2016）

40. Yunfei Zhou, Jianming Zhu, Bo Li,* Yong Zhang, Jia Feng, Adrian Hall, Jiye Shi,* Weiliang Zhu*. Access to Different Isomeric Dibenzoxazepinones through Copper-Catalyzed C-H Etherification and C-N Bond Construction with Controllable Smiles Rearrangement, Org. Lett., 2016 Feb 5;18(3):380-383. （IF 6.732 / 2015）

41. Jianming Zhu,# Xiaolong Li,# Guimin Wang, Bo Li,* Zhijian Xu, Shikai Tian, Adrian Hall, Jingshan Shen, Jiye Shi,* Weiliang Zhu*. Facile Synthesis of Substituted 4-Alkoxy-2-oxazolines and Exploration of the Reaction Mechanism, Synthesis, 2016 Feb, 48, 1331-1343. （IF 2.652 / 2015）

42. Zhao Li,# Jia Feng,# Kun Zou, Zhuo Yang, Yong Zhang, Zhijian Xu, Bo Li,* Jiye Shi,* Yiming Li, Weiliang Zhu,* Kaixian Chen. Facile Synthesis of 7-epi-Taxane and Its Derivatives and Preliminary Evaluation of Anticancer Activity, Chin. J. Chem. 2016 November 14, 34, 1165-1176. （IF 1.872 / 2015）

43. Guoxin Du, Yisu Li, Shunan Ma, Rui Wang, Bo Li,* Fujiang Guo,* Weiliang Zhu, Yiming Li.* Efficient Determination of the Enantiomeric Purity and Absolute Configuration of Flavanones by Using (S)‑3,3′-Dibromo-1,1′-bi-2-naphthol as a Chiral Solvating Agent, J. Nat. Prod. 2015 Dec 24;78(12):2968-74.（IF 3.798 / 2014）

44. Tao Jiang,# Yuren Zhou,# Zhuxi Chen,# Peng Sun, Jianming Zhu, Qiang Zhang, Zhen Wang, Qiang Shao, Xiangrui Jiang,* Bo Li,* Kaixian Chen, Hualiang Jiang, Heyao Wang,* Weiliang Zhu, Jingshan Shen. Design, Synthesis, and Pharmacological Evaluation of Fused β-homophenylalanine Derivatives as Potent Dipeptidyl Peptidase-4 Inhibitors，ACS Med Chem Lett. 2015 Apr 8;6(5):602-6.（IF 3.120 / 2014）

45. Tao Jiang,# Yuren Zhou,# Jianming Zhu,# Zhuxi Chen, Peng Sun, Qiang Zhang, Zhen Wang, Qiang Shao, Xiangrui Jiang,* Bo Li,* Heyao Wang,* Weiliang Zhu, Jingshan Shen. Design, Synthesis, and Pharmacological Evaluation of Highly Potent and Selective Dipeptidyl Peptidase-4 Inhibitors，Arch Pharm (Weinheim). 2015 Jun;348(6):399-407.（IF 2.043 / 2015）

46. Bo Li,# Gaihong Wang,# Zhijian Xu, Yong Zhang, Xiangui Huang, Bubing Zeng, Kaixian Chen, Jiye Shi,* Heyao Wang,* Weiliang Zhu.* Discovery of N-substituted 3-arylisoquinolone derivatives as antitumor agents originating from O-substituted 3-arylisoquinolines via [2,3] or [3,3] rearrangement，Eur. J. Med. Chem., 2014 Apr 22;77:204-10.（IF 3.432 / 2013）

47. Bo Li,# Gaihong Wang,# Mu Yang, Zhijian Xu, Bubing Zeng,* Heyao Wang,* Jingshan Shen, Kaixian Chen, Weiliang Zhu.* Overman rearrangement and PomeranzeFritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents，Eur. J. Med. Chem.，2013，70：677-684. （IF 3.499 / 2012）